Aims: Are there differences in the attitudes of physicians, parents and people with diabetes (PwD) towards digitalization and new technologies in diabetes and how do these change from 20- 2021?

Methods: In 20 and 2021, PwD and diabetologists in Germany were asked via online surveys about their attitudes and assessment of digitalization and new technologies in diabetology. 2019: 324 diabetologists (43% female, average age 52.2 years) and 3.427 PwD (47.7% female, 56.6% type 1 diabetes (T1D) , 25.5% type 2 diabetes (T2D) , 8.1% parents of children with diabetes; Ø 49.2±19.3 years) . 2021: 3diabetologists (48% female, average age 53.7 years) and 2.417 PwD (47.5% female, 57.8% type 1 diabetes (T1D) , 20.7% type 2 diabetes (T2D) , 19.0% parents of children with diabetes; Ø 47.7 years) .

Results: Parents (T1D) (2019: 89.5% positive; 2021: 91.7%) PwD-TD1 (2019: 85.3%; 2021: 91.1%) have more positive attitudes towards digitalization than PwD-T2D (2019: 73.3%; 2021: 87.1%) or diabetologists (2019: 75.8%; 2021: 81.9%) . Within 2 years, positive attitudes increased in all 4 groups. There was a great agreement between all 4 groups regarding the most important topics for the future of diabetology: AID systems were in first place in the ranking, followed by interoperability of systems, software for analysing glucose data and artificial intelligence.

Conclusions: PwD have very positive attitudes towards digitalization and new technologies in diabetes with only very small differences between TD1 and TD2. These are significantly higher than those of physicians. All groups have very high expectations for the further development of AID systems in particular.


B.Kulzer: Advisory Panel; Bayer AG, Bayer AG, Becton, Dickinson and Company, Becton, Dickinson and Company, Berlin-Chemie AG, Berlin-Chemie AG, Dexcom, Inc., Dexcom, Inc., Insulet Corporation, Novo Nordisk, Roche Diabetes Care, Sanofi, Sanofi-Aventis Deutschland GmbH, Research Support; Novo Nordisk, Roche Diabetes Care. N.Hermanns: Advisory Panel; Abbott Diabetes, Research Support; Becton, Dickinson and Company, Roche Diagnostics, Speaker's Bureau; Berlin-Chemie AG, Novo Nordisk, Sanofi. D.Ehrmann: Advisory Panel; Dexcom, Inc., Consultant; mySugr, Roche Diabetes Care, Speaker's Bureau; Berlin-Chemie AG, Dexcom, Inc. T.Roos: None. L.Heinemann: Board Member; Lifecare, Inc., Consultant; Becton, Dickinson and Company, Roche Diabetes Care, Stock/Shareholder; Profil Institut für Stoffwechselforschung GmbH, Science Consulting in Diabetes GmbH.

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at